<DOC>
	<DOCNO>NCT00120523</DOCNO>
	<brief_summary>The primary purpose study investigate safety pimecrolimus cream 1 % long-term treatment ( 5 year ) atopic dermatitis ( eczema ) patient less 12 month age compare topical corticosteroid ( TCS ) .</brief_summary>
	<brief_title>5-Year Safety Study Pimecrolimus Cream 1 % Infants 3 - 12 Months Age With Mild Moderate Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Aged 3 &lt; 12 month Diagnosis AD fulfil diagnostic criterion Seymour AD affect least 5 % total body surface area Investigator 's Global Assessment ( IGA ) score 2 3 , correspond mildtomoderate disease baseline Informed consent Phototherapy , systemic therapy ( e.g. , immunosuppressant , cytostatics ) , systemic corticosteroid within 4 week Topical tacrolimus pimecrolimus within 2 week Topical therapy ( e.g. , tar , topical corticosteroid ) within 3 day Immunocompromised ( e.g. , lymphoma , AIDS , WiskottAldrich Syndrome ) history malignant disease Active acute viral skin infection ( e.g . herpes simplex , herpes zoster , chicken pox ) , and/or clinically infect AD Failure thrive ( e.g. , weight height/length 5th percentile ) developmental abnormality head circumference less 5th 95th percentile Known hypersensitivity ingredient pimecrolimus cream 1 % topical corticosteroid Clinical condition AD accord investigator interfere evaluation</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Atopic dermatitis , child , infant , pimecrolimus</keyword>
</DOC>